Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children Novartis wins Swiss approval for Coartem Baby, first malaria drug for infants and young children Post ContentnvsRead More You might also be interested in reading Acadia expects more than $1B in sales for 2025. July 8, 2025 In Mainstream ← Previous post Next post →